InvestorsHub Logo
icon url

CD_98

05/21/04 3:16 PM

#7832 RE: blasher #7828

Listened to Frank, and he is okay but not as good as Malcolm.
He failed to go into very much detail as to why toxins released from gram negative bacterias kill and how these toxins are released by the bacteria. Would not have taken
that much time to explain, plus the fact that he was much too slow to explain why ssDNA expression has advantages over other means of treatment. IMO Malcolm gives a great deal of detail and explaination in a short period of time.

And for Larry's information: again Frank reiterated the FACT that these are preclinical trials.

Looking for the price to drift down. Not too much support here
so buying opportunities may be presenting themselves soon.
JMO

CD_98
icon url

CD_98

05/21/04 3:17 PM

#7833 RE: blasher #7828

Listened to Frank, and he is okay but not as good as Malcolm.
He failed to go into very much detail as to why toxins released from gram negative bacterias kill and how these toxins are released by the bacteria. Would not have taken
that much time to explain, plus the fact that he was much too slow to explain why ssDNA expression has advantages over other means of treatment. IMO Malcolm gives a great deal of detail and explaination in a short period of time.

And for Larry's information: again Frank reiterated the FACT that these are preclinical trials.

Looking for the price to drift down. Not too much support here
so buying opportunities may be presenting themselves soon.
JMO

CD_98
icon url

CD_98

05/21/04 3:17 PM

#7834 RE: blasher #7828

Listened to Frank, and he is okay but not as good as Malcolm.
He failed to go into very much detail as to why toxins released from gram negative bacterias kill and how these toxins are released by the bacteria. Would not have taken
that much time to explain, plus the fact that he was much too slow to explain why ssDNA expression has advantages over other means of treatment. IMO Malcolm gives a great deal of detail and explaination in a short period of time.

And for Larry's information: again Frank reiterated the FACT that these are preclinical trials.

Looking for the price to drift down. Not too much support here
so buying opportunities may be presenting themselves soon.
JMO

CD_98